“Melanoma Bridge 2018”
Naples – November 29th – December 1st 2018

PRELIMINARY PROGRAM

**Not included in the CME accredited program
*invited faculty

November 29th (Thursday)
17:00  18:00  Registration**
18:00  18:30  Opening Session Lecture**, Magdalena Thurin

November 30th (Friday)
9:00  9:30  Registration**

Session - Melanoma as a model system
Chairperson: Giuseppe Masucci, Olivier Michelin
9:30  9:50  Neoadjuvant and adjuvant, Sanjiv Agarwala
9:50  10:10  Biomarkers in immunotherapy of melanoma: an update, Claus Garbe
10:10  10:30  Combining MAPK and PD-1/L1 inhibitors- lessons from patients and mice, Roger Lo
10:30  10:50  Clinical evidence emerging from radiation and Immunotherapy, Silvia Formenti
10:50  11:10  Discussion on melanoma as a model system, Giuseppe Masucci, Olivier Michelin
11:10  11:25  Break**
11:25  12:25  Oral Communications**
12:25  13:25  Symposium Title to be defined** - Sponsored by MSD
  Paolo A. Ascierto, Mario Mandalà
13:25  14:10  Lunch**

Session - Mechanisms of resistance and drivers of response
Chairpersons: Gerardo Botti, Giuseppe Palmieri
14:10  15:10  Symposium
15:10  15:30  Exosomes, Soldano Ferrone
15:30  15:50  Microbiota, Laurence Zitvogel
15:50  16:10  Title to be defined, Thomas Gajewski
16:10  16:30  Title to be defined, Abi Diab
16:30  16:50  Discussion on mechanisms of resistance and drivers of response, Gerardo Botti, Giuseppe Palmieri
16:50 17:05  Break**
17:05 18:05  Oral Communications**
18:05 18:20  Conclusions, Gerardo Botti, Giuseppe Palmieri

December 1st (Saturday)
Session - Emerging strategies
Chairpersons: Corrado Caracò, Alfredo Budillon
9:30 9:50  Translational research in the therapeutic landscape for metastatic melanoma, Reinhard Dummer
9:50 10:10  Title to be defined, Igor Puzanov
10:10 10:30  Advancing the understanding and treatment of melanoma CNS metastases, Michael Davies
10:30 10:50  Emerging strategies for combination immunotherapy in melanoma, Jason Luke
10:50 11:10  Discussion
11:10 11:40  Lecture – Target therapy and Immunotherapy: rational for combination and future perspectives, Paolo A. Ascierto
11:40 11:55  Break**
11:55 12:55  Oral Communications**
Chairperson: Paolo A. Ascierto
12:55  A new paradigm: IO as adjuvant, Omid Hamid
13:15  Novel combination strategies, Paolo A. Ascierto
13:35  Discussion on IO adjuvant therapy and novel combination, Paolo A. Ascierto, Omid Hamid
13:55 14:30  Lunch**

Session - Great Debate
Chairpersons: Alessandro Testori, Franco Perrone
14:30 15:30  Symposium
15:30 16:00  Is OS still the main endpoint? Yes or no - Alexander Eggermont, Paolo Bruzzi
16:00 16:10  Discussion on Is OS still the main endpoint? Alessandro Testori, Franco Perrone, Alexander Eggermont, Paolo Bruzzi
16:10 16:40  Is anti CTLA-4 still the good drug to combine with anti PD-L1? Yes or no - Paolo A. Ascierto, Omid Hamid
16:40 16:50  Discussion on Is anti CTLA-4 still the good drug to combine with anti PD-L1?, Alessandro
16:50  17:20  Adjuvant vs neoadjuvant - Alexander van Akkooi, John Kirkwood

17:20  17:30  Discussion on Adjuvant vs neoadjuvant, Alessandro Testori, Franco Perrone, Alexander van Akkooi, John Kirkwood

17:30  17:50  Conclusions, Paolo A. Ascierto, Corrado Caracò, Igor Puzanov

Presidency

Paolo A. Ascierto  Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Corrado Caracò  Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Igor Puzanov  Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Scientific Board

Sanjiv Agarwala  Chief of Medical oncology and Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, Pennsylvania

Paolo A. Ascierto  Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Carlo Bifulco  Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Lisa H. Butterfield  SITC, University of Pittsburgh, Pennsylvania, US

Corrado Caracò  Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Reinhard Dummer  Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Bernard A. Fox  Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Jerome Galon  Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Claus Garbe  University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

Giuseppe Masucci  Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
Michael Postow  
Memorial Sloane Kettering Cancer Center, New York, New York

Igor Puzanov  
Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Magdalena Thurin  
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Invited Faculty

Sanjiv Agarwala  
Chief of Medical oncology and Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, Pennsylvania

Paolo A. Ascierto  
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Gerardo Botti  
Head of the Department of Diagnostic Pathology, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Paolo Bruzzi  
Clinical Epidemiology Unit Director, University Hospital “San Martino”, Genova, Italy

Alfredo Budillon  
Staff Member and Senior Scientist of Molecular Biology and Viral Oncology Unit National, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Corrado Caracò  
Director of Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Michael Davies  
Associate Professor, Department of Melanoma Medical Oncology, Department of Systems Biology, University of Texas MD Anderson Cancer Center, Texas, US

Adi Diab  
Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Reinhard Dummer  
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Alexander Eggermont  
Director, Gustave Roussy Cancer Campus Grand Paris Villejuif, France

Soldano Ferrone  
Massachusetts General Hospital, Boston, Massachusetts, US

Silvia Formenti  
Department of Radiation Oncology - Weill Cornell Medical College, NY

Thomas F. Gajewski  
Oncology and Immunology Professor, Department of Pathology and Department of Medicine, Section of Hematology/Oncology, Chicago, Illinois, US

Claus Garbe  
University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

Omid Hamid  
Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute, Los Angeles, CA

John M. Kirkwood  
Usher Professor of Medicine, Dermatology and Translational Science and Director of Melanoma and Skin Cancer Program, Department of Medicine,
Metastatic melanoma represents a challenging clinical situation due, until relatively recently, to a paucity of effective treatment options. Melanoma treatment landscape changed in 2011 with the approval of the first...
anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival. Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response. Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma. The new therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

However, many questions still remain unanswered, beginning with the identification of melanoma patients who will derive most benefit from different treatments and on the biomarkers that can be employed to help select patients for treatment. Other pending questions that will drive the discussion at Melanoma Bridge are:

- Is melanoma a model system in cancer treatment?
- What do we know of the mechanisms of resistance and of drivers of response?
- Which are the most valuable emerging strategies?

Conclusions will be drawn after the “Great Debate” session, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed: (1) whether overall survival is still the main endpoint; (2) whether anti CTLA-4 is still the good drug to combine with anti PD-L1 (programmed death ligand 1); (3) whether neo-adjuvant should be preferred over adjuvant therapy.

Presidents of the event are Paolo A. Ascierto (INT, Naples, Italy), Igor Puzanov (Roswell Park Cancer Center, New York), and Corrado Caracò (INT, Naples, Italy), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients.